Recombinant Human Latent TGF-beta 1 Protein
R&D Systems, part of Bio-Techne | Catalog # 299-LT
Soon to be discontinued. New Cat# will be 299-LTB
Key Product Details
Product Specifications
Source
Chinese Hamster Ovary cell line, CHO-derived human TGF-beta 1 protein
Leu30-Ser390
Leu30-Ser390
Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Leu30 (LAP) & Ala279 (Mature)
Predicted Molecular Mass
28.5 kDa (LAP) & 12.8 kDa (Mature), Monomer
SDS-PAGE
36-42 kDa & 11 kDa, reducing conditions
80-95 kDa & 24 kDa, non-reducing conditions
80-95 kDa & 24 kDa, non-reducing conditions
Activity
Measured by its ability to inhibit the IL-4-dependent proliferation of HT-2 mouse T cells. Tsang, M. et al. (1995) Cytokine 7:389.
The ED50 for this effect is 10-70 ng/mL before acid activation and 0.15‑0.9 ng/mL after acid activation.
The ED50 for this effect is 10-70 ng/mL before acid activation and 0.15‑0.9 ng/mL after acid activation.
Reviewed Applications
Read 3 reviews rated 5 using 299-LT in the following applications:
Scientific Data Images for Recombinant Human Latent TGF-beta 1 Protein
Recombinant Human Latent TGF-beta 1 Protein Bioactivity
Recombinant Human Latent TGF-beta beta1 (Catalog # 299-LT) after acid activation inhibits Recombinant Mouse IL-4 (Catalog # 404-ML) induced cell proliferation in the HT-2 mouse T cell line. The ED50 for this effect is 0.15-0.9 ng/mL after acid activation.
Recombinant Human Latent TGF-beta 1 Protein SDS-PAGE
1 μg/lane of Recombinant Human Latent TGF‑ beta1 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silverstaining, showing bands at 11, 36-42 kDa (R) and 24, 80-95 kDa (NR).Formulation, Preparation and Storage
Carrier Free
What does CF mean?CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
Carrier: 299-LT
| Formulation | Supplied as a 0.2 μm filtered solution in PBS and Glycerol with BSA as a carrier protein. |
| Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Carrier Free: 299-LT/CF
| Formulation | Supplied as a 0.2 μm filtered solution in PBS and Glycerol. |
| Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: TGF-beta 1
TGF- beta1 (transforming growth factor beta 1) and the closely related TGF-beta 2 and -3 are members of the large TGF-beta superfamily. TGF- beta proteins are highly pleiotropic cytokines that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1-3). Human TGF-beta 1 cDNA encodes a 390 amino acid (aa) precursor that contains a 29 aa signal peptide and a 361 aa proprotein (4). A furin-like convertase processes the proprotein within the trans-Golgi to generate an N‑terminal 249 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF-beta 1 (4-6). Disulfide-linked homodimers of LAP and TGF-beta 1 remain non‑covalently associated after secretion, forming the small latent TGF-beta 1 complex (4-8). Purified LAP is also capable of associating with active TGF-beta with high affinity, and can neutralize TGF-beta activity (9). Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (5-7). TGF-beta activation from latency is controlled both spatially and temporally, by multiple pathways that include actions of proteases such as plasmin and MMP9, and/or by thrombospondin 1 or selected integrins (5, 8). The LAP portion of human TGF-beta 1 shares 91%, 92%, 85%, 86% and 88% aa identity with porcine, canine, mouse, rat and equine TGF-beta 1 LAP, respectively, while the mature human TGF-beta 1 portion shares 100% aa identity with procine, canine and bovine TGF-beta 1, and 99% aa identity with mouse, rat and equine TGF-beta 1. Although different isoforms of TGF-beta are naturally associated with their own distinct LAPs, the TGF-beta 1 LAP is capable of complexing with, and inactivating, all other human TGF-beta isoforms and those of most other species (9). Mutations within the LAP are associated with Camurati-Engelmann disease, a rare sclerosing bone dysplasia characterized by inappropriate presence of active TGF-beta 1 (10).
References
- Dunker, N. and K. Krieglstein (2000) Eur. J. Biochem. 267:6982.
- Wahl, S.M. (2006) Immunol. Rev. 213:213.
- Chang, H. et al. (2002) Endocr. Rev. 23:787.
- Derynck, R. et al. (1985) Nature 316:701.
- Dabovic, B. and D.B. Rifkin (2008) “TGF-beta Bioavailability” in The TGF-beta Family. Derynck, R. and K. Miyazono (eds): Cold Spring Harbor Laboratory Press, p. 179.
- Brunner, A.M. et al. (1989) J. Biol. Chem. 264:13660.
- Miyazono, K. et al. (1991) EMBO J. 10:1091.
- Oklu, R. and R. Hesketh (2000) Biochem. J. 352:601.
- Miller, D.M. et al. (1992) Mol. Endocrinol. 6:694.
- Janssens, K. et al. (2003) J. Biol. Chem. 278:7718.
Long Name
Transforming Growth Factor beta 1
Alternate Names
TGF beta1, TGFB, TGFB1, TGFbeta 1
Gene Symbol
TGFB1
UniProt
Additional TGF-beta 1 Products
Product Documents for Recombinant Human Latent TGF-beta 1 Protein
Product Specific Notices for Recombinant Human Latent TGF-beta 1 Protein
For research use only
Loading...
Loading...